Terminating Routine Cord Blood RhD Typing of the Newborns to Guide Postnatal Anti-D Immunoglobulin Prophylaxis Based on the Results of Fetal RHD Genotyping
Fetal Diagnosis and Therapy · 2023
DOI: 10.1159/000531694 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fetal Diagnosis and Therapy, 2023. Verfasst von Monica Stensrud und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway. Hauptthemen laut MEDLINE: Rh Isoimmunization, Maternal Health Services. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Targeted routine antenatal prophylaxis with anti-D immunoglobulin (Ig) only to RhD-negative pregnant women who carry RhD-positive fetuses (determined by fetal RHD genotyping) has reduced D-alloimmunization significantly when administered in addition to postnatal prophylaxis. Achieving high analysis sensitivity and few false-negative fetal RHD results will make RhD typing of the newborn redundant. Postnatal prophylaxis can then be given based on the result of fetal RHD genotyping. Terminating routine RhD typing of the newborns in cord blood will streamline maternity care. Accordingly, we compared the results of fetal RHD genotyping with RhD typing of the newborns.
Methods
Fetal RHD genotyping was performed, and antenatal anti-D Ig was administered at gestational week 24 and 28, respectively. Data for 2017–2020 are reported.
Results
Ten laboratories reported 18,536 fetal RHD genotypings, and 16,378 RhD typing results of newborns. We found 46 false-positive (0.28%) and seven false-negative (0.04%) results. Sensitivity of the assays was 99.93%, while specificity was 99.24%.
Conclusion
Few false-negative results support the good analysis quality of fetal RHD genotyping. Routine cord blood RhD typing will therefore be discontinued nationwide and postnatal anti-D Ig will now be given based on the result of fetal RHD genotyping.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway.
- Department of Immunology and Transfusion Medicine, St. Olavs University Hospital, Trondheim, Norway.
- Department of Laboratory Medicine, Blood Bank, Nordland Hospital, Bodø, Norway.
- Department of Immunology and Transfusion Medicine, Akershus University Hospital, Lørenskog, Norway.
- Department of Laboratory Medicine, University Hospital of North Norway, Tromsø, Norway.
- Department of Immunology and Transfusion Medicine, Stavanger University Hospital, Stavanger, Norway.
Zitieren
APA
Stensrud, M., Bævre, M. S., Alm, I. M., Wong, H. Y., Herud, I., Jacobsen, B., de Vos, D. D. J. A., Stjern, H. E., Sørvoll, I. H., Barane, J. B., Bagås, T. E., Rasmussen, M., Ulvahaug, N., Wamstad, V., Tomter, G., & Akkök, C. A. (2023). Terminating Routine Cord Blood RhD Typing of the Newborns to Guide Postnatal Anti-D Immunoglobulin Prophylaxis Based on the Results of Fetal RHD Genotyping. Fetal Diagnosis and Therapy. https://doi.org/10.1159/000531694
Vancouver
Stensrud M, Bævre MS, Alm IM, Wong HY, Herud I, Jacobsen B, et al. Terminating Routine Cord Blood RhD Typing of the Newborns to Guide Postnatal Anti-D Immunoglobulin Prophylaxis Based on the Results of Fetal RHD Genotyping. Fetal Diagnosis and Therapy. 2023. doi:10.1159/000531694
BibTeX
@article{Stensrud2023,
author = {Stensrud, Monica and Bævre, Mette Silihagen and Alm, Inger Margit and Wong, Ho Yi and Herud, Ida and Jacobsen, Barbora and de Vos, Dijanne Dicky Jannie Anne and Stjern, Helena Eriksson and Sørvoll, Ingvild Hausberg and Barane, Janne Brit and Bagås, Tonje Espeland and Rasmussen, Mona and Ulvahaug, Norunn and Wamstad, Vendula and Tomter, Geir and Akkök, Cigdem Akalin},
title = {Terminating Routine Cord Blood RhD Typing of the Newborns to Guide Postnatal Anti-D Immunoglobulin Prophylaxis Based on the Results of Fetal RHD Genotyping},
journal = {Fetal Diagnosis and Therapy},
year = {2023},
doi = {10.1159/000531694}
}
EUVIMED